Skip to main content
. 2017 Jan 5;2017:8305976. doi: 10.1155/2017/8305976

Table 2.

Composition of preliminary trial batch with individual disintegrant and their evaluation parameters.

Ingredients (mg) F A1 F A2 F A3 F A4 F A5 F A6 F A7 F A8
CTZ 10 10 10 10 10 10 10 10
CCS 5 10 15 20
(2.5%) (5%) (7.5%) (10%)
HRM 10 20 30 40
(5%) (10%) (15%) (20%)
Pearlitol SD 200 149 144 139 134 144 134 124 114
Sorbitol 20 20 20 20 20 20 20 20
Otherexcipients 12 12 12 12 12 12 12 12
Aspartame 4 4 4 4 4 4 4 4

Evaluation
Parameters

DT (sec) 31 ± 2 18 ± 2.2 25 ± 1.3 28 ± 2.3 39 ± 0.33 28 ± 0.12 36 ± 0.23 49 ± 0.32
F (%) 0.93 0.91 1.11 1.34 0.49 0.31 0.79 0.87
Wetting time (sec) 27 16 24 22 36 25 33 47
DR at 25 min 98.24 98.99 98.72 97.47 93.32 98.32 89.45 87.33

Net tablet weight: 200 mg; batch size: 50 CTZ ODTs.

Note. The amount of all the ingredients was calculated on the basis of net weight of one tablet (200 mg). For the preliminary trial batch four varied concentrations of CCS and HRM (ΔCCS: 2.5%–10%; ΔHRM: 5%–20%) were trialed for desired tablet properties. D-sorbitol (10%) and aspartame (2%) as sweetening agent were used to mask the inherent bitter taste of cetirizine hydrochloride in all the trial formulations.

Other excipients used were magnesium stearate, 2 mg (1%); aerosil, 2 mg (1%); talc, 2 mg (1%); and flavour, 6 mg (3%).